LEPR and Obesity: In 2020, the Food and Drug Administration (FDA) approved the first treatment involving the MC4R agonist setmelanotide for chronic weight management in adult and pediatric patients at least 6 years of age with obesity due to three rare genetic conditions: POMC, LEPR, or PCSK1 deficiency.